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Background: High-intensity focused ultrasound (HIFU) is a promising, non-invasive technique in treating benign
thyroid nodules (TNs). The aim of this study was to evaluate the efficacy of HIFU to induce clinically meaningful
shrinkage in benign predominantly solid TNs and to identify variables that influence or predict the magnitude of
TN volume reduction.
Methods: For each of ten subjects, HIFU treatment was conducted on a single nodule. Nodular volume was measured
sonographically at baseline and at 3 months post-procedure. Nodular function and early treatment assessment was
done scintigraphically.
Results: Median nodular volume reduction was 0.7 ml absolute and 48.8% relative to pre-interventional size (p < 0.05).
Absolute shrinkage was negatively correlated with the average treatment depth (τ = −0.61, p < 0.05). Absolute nodular
volume was positively correlated with the scintigraphic nodular uptake reduction (τ = 0.66, p < 0.05).
Conclusions: HIFU treatment of benign predominantly solid TNs appears to be safe and effective for inducing nodular
shrinkage. Despite potential for improvement, a single treatment session with HIFU is already a viable alternative to
more standard methods. The feasibility of multiple HIFU treatments requires further investigation. Due to the small
sample size, the findings of this analysis need conformation by larger studies.
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Thyroid nodules (TNs) are common in western popula-
tions, most being of a benign nature [1]. Apart from au-
tonomous nodular overproduction, all issues related to
these nodules, such as swallowing disorders, throat
tightness, hoarseness, neck pain or discomfort, are directly
caused by TNs’ volume which puts pressure on neighbour-
ing anatomical structures. Additionally, cosmetic problems
associated with TNs are directly related to the nodules’
volume.
For many years, surgery and radioiodine therapy (RIT)
were the only options for treatment of benign TNs. Both
procedures are costly and the former is not without risk* Correspondence: niklas.fehre@online.de
†Equal contributors
1Department of Nuclear Medicine, University Hospital Frankfurt,
Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
Full list of author information is available at the end of the article
© 2015 Korkusuz et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.[2]. Moreover, some patients are uncomfortable with these
methods due to their invasive or radioactive nature [3].
Additional techniques that have been widely discussed
in recent years include ethanol injection into the TN
(ethanol ablation (EA)) [4,5], thermal destruction of the
nodular tissue via the application of microwave ablation
(MWA) [6,7], interstitial laser photocoagulation (ILP)
[8-10] and radio-frequency ablation (RFA) [11,12]. Several
studies report that these methods are effective and have
low complication rates [13]. Such techniques are minim-
ally or not at all invasive and, in many cases, are less costly
than surgery or RIT. However, relative to thyroidectomy
or RIT, assessments are lacking of these methods’ risks,
costs, long-term clinical outcomes and patient satisfac-
tion [9].
To date, use of non-invasive tissue ablation by high-
intensity focused ultrasound (HIFU) has been reported in
a number of indications including uterine fibroids [14],al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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under development for liver and kidney tumours [17].
To our knowledge, the application of HIFU to TN has
only been reported in two preclinical studies [18,19] and
one human case study [20]. The method’s ability to in-
duce locally limited ablation, as opposed to efficacy, was
evaluated histologically in a study where patients were
treated with HIFU prior to scheduled thyroidectomy [21].
In living human tissue, temperatures between 60°C and
100°C induce coagulation necrosis without vaporization
and carbonation [22]. Thermal ablation uses this method
without inflicting damage to surrounding structures, pro-
viding a method to inflict precise localized destruction of
the target structure. In the case of HIFU, this can be done
even without surgical penetration of the skin. As ablated
tissue is disintegrated over time by immunology cells, the
intervention can cause a significant shrinkage of the target
structure.
The objectives of this study were to quantify 3-month
shrinkage of benign TNs in humans resulting from a
single HIFU treatment session and to characterize TN
features having potential to promote and/or predict clin-
ically meaningful reduction in nodule volume.
Methods
Recruitment
This study was limited to ten patients only. According
to inclusion and exclusion criteria, the first ten recruits
could all be included in the study. Recruitment was closed
afterwards. Recruitment took place in late 2013, and all
treatment was done in January 2014. As one patient re-
ceived therapy additional to HIFU treatment, this analysis
is based on data of the nine remaining patients.
Inclusion criteria
Patients over 18 years of age with at least one benign
thyroid nodule and associated issues such as neck pain,
hoarseness, swallowing disorders, discomfort, cosmetic
concerns and/or thyrotoxicosis, who either refused sur-
gery or RIT or who were contraindicated for them, were
included in the study.
Exclusion criteria
Patients with malignant nodules were excluded. Malig-
nancy was diagnosed by atypical findings in preliminary
99mTc-MIBI scintigraphy and confirmed by histological
indication of follicular proliferation based on fine-needle
aspiration biopsy (FNAB). Also excluded were patients
with target nodules close to sensible structures like the
trachea, oesophagus, recurrent nerve and carotid artery.
Patients who showed any contraindication to HIFU were
excluded. Contraindications are recurrent nerve anom-
alies and target volumes not clearly circumscribable in
B-mode ultrasound (US).If a patient presented with multiple TNs, the one chosen
for treatment was the one primarily responsible for patient
symptoms.
HIFU treatment was presented as an alternative to
MWA, and patients were informed of known procedure
risks (pain, recurrence of the treated nodule, vocal cord
palsy, skin burn, tracheal and oesophageal injuries). All
participating patients gave written informed consent. The
study was approved by the ethics commission of the
University Hospital Frankfurt.
Equipment
HIFU treatment was conducted with the US-guided
EchoPulse® (Theraclion SA, Malakoff, France). The guid-
ing US operates at 7.5 to 12 MHz, and the therapeutic
HIFU emits pulses at 3 MHz with a maximum sound
power of 125 W. Both guiding and therapeutic US are
emitted by a probe held by a robotic arm. The probe emit-
ting the imaging US is placed in the middle of the HIFU
emitter, so that the focal point of the therapeutic beam is
always displayed in the centre of the guiding US image.
The physician plans treatment by defining the target
area and sensible structures at about 10 to 20 sagittal
and transversal section plane images of the guiding US
at the EchoPulse® user interface. Security margins of 2 mm
to the carotid, 5 mm to the skin and at least 3 mm to the
trachea are automatically created by the EchoPulse®, and
treatment in those zones is blocked. After treatment
and non-treatment areas are defined, the HIFU device
proposes a layer of treatment voxels. These so-called treat-
ment sites have the approximate form of a rice corn; their
long sides adjoin each other. Treatment sites are displayed
within the guiding US image and can be deselected manu-
ally and thus excluded from treatment at any time.
Each HIFU pulse of 4-s duration is directed at one site
within the nodular target volume, a focusing that is cap-
able of inducing temperatures between 60°C and 80°C at
the target ellipsoid site (diameter 2 mm, length 9 mm).
As treatment sites directly border one another, the dis-
tance between two focal point centres is 2 mm. During
the inter-pulse cooling period, the robotic arm redirects
the probe at the next site. Cooling is provided by a circu-
lating liquid of 10°C within a plastic balloon positioned at
the forefront of the probe. This cooling of the skin above
the treatment area prevents pre-focal tissue damage.
To avoid incongruency between planning and actual treat-
ment, a laser-based distance measurement is implemented.
This system automatically stops treatment if changes above
1 mm in the span between the robotic arm holding the
probe and laser and the patient’s skin are registered.
Procedure
The treatment was planned and carried out with the
EchoPulse® user interface by a trained physician. To ensure
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potentially harmful energy than necessary, initial test pulses
were emitted to adjust US intensity to just below the point
where the so-called US-detectable “heat bubbles” indicate
sufficient heating of TN tissue to induce necrosis.
If tissue is sufficiently heated, decentralized development
of steam leads to the formation of the so-called heat- or
microbubbles. Wood et al. [23] report that US-detectable
microbubble generation in different human types of tissue
starts somewhere between 80°C and 90°C.
The detection of heat bubbles thus indicates tempera-
tures of around 80°C–90°C, while only temperatures of
above 60°C are necessary to induce the desired necrosis.
To limit the applied energy (which always needs to pass
through overlying tissue that we wanted to stay unharmed),
we operated the HIFU just below the point of heat bubble
formation. Figure 1 shows an exemplary nodule before and
immediately after an initial test pulse. The clearly visible so-
called hyperechoic mark (HEM) consists of microbubbles
and indicates temperatures above 80°C.
During treatment, the planned outlines of the target
area and sensible structures are displayed at all times, as
are the actual anatomical localizations due to the under-
lying B-mode guiding US imaging. A potential deviationFigure 1 Visual feedback during initial test pulse. During initial
test pulses, beam intensity was set to be just below the point where
the generation of a so-called hyperechoic mark (HEM) indicates
temperatures above 80°C–90°C. This mark is visible in B-mode US
due to the hyperechogenic character of microbubbles. These consist of
steam. Shown is an exemplary nodule before (A) and directly after (B)
such a test pulse. Clearly visible is the HEM, which vanishes within
seconds afterwards.of the planned treatment grid and reality, if not detected
by the laser measurement, can be easily spotted by the
performing physician. In this case, the treatment can be
manually interrupted until congruency is restored by
probe repositioning. Such probe readjustments may be
done manually or via steering the robotic arm using the
interface. Inter-pulse probe repositioning to target the
next treatment site is done automatically.Baseline evaluation and endpoints
Before HIFU treatment, nodules were assessed for size,
structure and exact location using B-mode US imaging.
Functional activity was evaluated using 99mTc-pertechnetate
scintigraphy (75 MBq, imaging 20 min post-administration
with a thyroid-specific scintillation camera (Mediso
Nucline® TH/22, acquisition time: 300 s, matrix: 128 ×
128 × 16, low-energy collimator)). Nodules presenting
as hypofunctional in this imaging were further examined
using 99mTc-MIBI (441 MBq, imaging 10 and 60 min
post-administration with the same camera mentioned
above, with 500-s acquisition time and 128 × 128 × 16
matrix) as well as FNAB cytology. Malignancy could be
ruled out in all cases.
Due to reactive edema formation, ablative effects of
the HIFU therapy are not quantifiable sonographically
immediately after intervention (see Figure 2). Early as-
sessment of treatment was done by scintigraphic means
1 day after the procedure. Scintigraphic imaging was done
according to guidelines.
Nodular volume was measured again at 3 months post-
ablation by a sonograph using the formula V = h ×w × d /
2.09, with h, w and d representing height, width and depth,
respectively. All sonographic examinations were done by
KH and performed with a Sonix Touch Ultrasound system
(Ultrasonix Medical Corporation, Richmond, Canada).
Maximal nodular dimensions were measured in trans-
versal and sagittal section plane B-mode US images. QA
was ensured as all measurements were validated by a radi-
ologist with specific sonographical experience.
The effect of HIFU treatment on nodule volume in terms
of difference between 3 months as baseline was quantified
in both absolute and relative terms (i.e. percentage of
baseline).
Scintigraphic uptake reduction is reported as the relative
target area background adjusted uptake reduction in rela-
tion to the total thyroidal uptake. These are measured
within the region of interest using 99mTc-pertechnetate
for hot and indifferent nodules and 99mTc-MIBI for cold
nodules.
Procedure characteristics recorded by EchoPulse® and
provided in treatment reports included treatment depth,
procedure time, total energy delivered per patient and
energy delivered to the target site.
Figure 2 Short-term change of nodule appearance due to HIFU treatment. An exemplary nodule in B-mode US before (A) and directly after
the completion of HIFU treatment (B). An estimation of ablation magnitude is not possible due to reactive edema formation.
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Statistical analysis was done with the free R statistical
software (R Core Team 2013); http://www.R-project.org/).
Due to the small sample size, the test for a significant
decrease of nodular volume was performed with non-
parametric methods (one-sided Wilcoxon signed rank
test). Significance is defined as p < 0.05.
Due to the small sample size and unknown underlying
distributions, correlations are reported using Kendall’s τ
and tested against the null hypothesis of τ = 0. Significance
is defined as p < 0.05. Tests for a significant difference in
nodular volume reduction between solid and echocomplex
as well as between hot and non-hot nodules were con-
ducted using a two-sided Wilcoxon test.
Correlations are rounded down and reported up to the
second position after the decimal point; p values are
brought up to a round figure at the second decimal place.
Other values are reported up to the first decimal place
rounded upwards from above 0.x5 and downwards below.
Results
Patients and baseline characteristics
Of the ten treated subjects, one was excluded from the
current analysis as he received combined therapy with
HIFU with subsequent RIT to reduce the necessary radi-
ation dose. Data of the nine remaining patients (seven
females (77.7%) with median age 52 (36–80)) who under-
went HIFU treatment for one nodule each are included in
this analysis. All treated nodules were benign (three hot
or indifferent, six cold, four solid, five echocomplex; withpre-intervention volumes from 0.8 to 7.7 ml, median
3.5 ml). See Table 1 for more information on patients.
Procedure characteristics
Mean treatment depth ranged from 13.6 to 24.3 mm
(median 18.3 mm), treated volume per patient from 0.8
to 2.1 ml (median 1.3 ml), total energy delivery per patient
from 5.7 to 12.5 kJ (median 9.9 kJ) and delivered energy
per site from 113.1 to 192.8 J (median 163 J). The number
of treated sites ranged from 34 to 87 (median 54). Each
site was treated with a 4-s pulse; duration of inter-pulse
cooling intervals was positively dependent on pulse inten-
sity and took 20 to 40 s. A median of 45.5% of the total
nodular volume could be treated (range 26.6% to 57.1%).
Median treatment time was 62 min (range 42 to 96 min).
Patients received therapy either under local anaesthesia
with Mecain or no anaesthesia at all. Treatment was done
on an outpatient basis and was completed as planned in
all cases.
Reduction of nodule volume
All nine TNs decreased in size relative to baseline at
3 months after HIFU therapy. Absolute decrease ranged
from 0.4 to 4.7 ml (median 0.7 ml, p = 0.01; Figures 3
and 4), and relative volume reduction ranged from 11.4%
to 75% (median = 48.8%). See Table 2 for more informa-
tion on the treated nodules.
Amongst tested variables, correlation to absolute nodu-
lar volume reduction was significant only for mean treat-
ment depth (τ = −0.61, p = 0.03) and scintigraphic nodular
Table 1 Patient characteristics
Patient number Age Sex Clinical diagnosis Previous treatment on
the thyroid
TN-related symptoms Pathological findings
in FNAB
1 50 M Struma nodosa with
hypofunctional nodule
Globus pharyngis No indication for
malignancy





3 36 F Struma nodosa with
hypofunctional nodule
Swallowing disorder No indication for
malignancy




L-Thyroxin medication Several symptoms associated with
hyperthyroidism, globus pharyngis
5 44 F Thyroidea nodosa with
hypofunctional nodule




6 80 F Hypofunctional nodule Globus pharyngis No indication for
malignancy




Sensation of throat tightness,
dyspnea on exertion, swallowing
disorder
8 50 F Hypofunctional nodule RIT due to focal thyroidical
autonomy 2 years ago
Swallowing disorder No indication for
malignancy
9 58 F Struma nodosa with
hypofunctional nodule
Globus pharyngis No indication for
malignancy
This table shows detailed information on each patient.
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correlated to relative nodular volume reduction with (τ =
0.44, p = 0.12).
Correlations of absolute nodular volume reduction to
pre-intervention nodular volume (τ =0.38, p = 0.19),
treated volume (τ = −0.11, p = 0.77), total energy delivered
per nodule (τ= 0.05, p= 0.92), nodular structure (solid or
echocomplex; p= 0.72) and nodular functionality (hot or not;
p = 0.56) had no significant impact on volume reduction.Figure 3 Volume reduction. Median nodular volume reduction within
3 months after HIFU treatment was 0.7 ml. The asterisk indicates a
significant change with p < 0.05.In three of nine TNs, volume reduction as reported in
the treatment report was larger than the treated volume,
and in six cases, the reverse occurred. Median treatment
depth for the former was 14.4 mm and for the latter
19.9 mm.
Euthyrosis (normal ranges for TT3, TT4 and TSH
are 1.0–3.3 nmol/l, 55–170 nmol/l and 0.3–4.0 mE/l,
respectively) was achieved or preserved in eight cases;
one patient with an autonomous hyperfunction presented
a hidden hyperthyroidism as expected, as HIFU treatment
was done on an additional cold TN.
Safety
No major complications such as vocal cord palsy; tracheal,
vagal or oesophageal injuries; infections; or nodule rupture
were observed. Patients were asked to report the pain they
felt during the interventional HIFU pulses and directly
after treatment completion using a numeric rating scale
reaching from 0 to 10. Median pain level during treatment
beams was 5.5 (range 3 to 7), while it was only 2 (range 0
to 4) right after the completion of interventions. All pa-
tients reported discomfort on the throat due to probe
pressure and cooling; most described a spreading of pain to-
wards the neck, scapula, trapezius muscle or arm over time.
Most patients showed a slight reddening of the skin and
mild swelling above the treated nodule 24 h after the
treatment; one patient developed a small hematoma at
the puncture location of the local anaesthesia. No pa-
tient reported any pain 24 h after treatment.
Figure 4 Volume measurement. Sonographical volume measurement of an exemplary thyroidal nodule before (A) and 3 months after (B) HIFU treatment.
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needing any treatment. During the next 3 months, no fur-
ther complications were observed. Informal reports indi-
cate that acceptance of treatment amongst patients was
very good.
Discussion
Strengths and weaknesses of HIFU
HIFU’s main advantage relative to local thermal abla-
tion techniques like RFA or MWA is non-invasiveness.
Consequently, HIFU requires less anaesthetic, makesinfection highly unlikely and precludes scar formation.
As such, patient acceptance of it is very high.
Non-invasiveness is also the source of HIFU’s relative
weakness in that its energy must be transported through
overlying, non-target tissue before reaching the ablation
area, as opposed to RFA and MWA where ablation energy
is applied directly to affected areas. As a result, HIFU’s main
technical challenge is avoidance of damage to pre-focal tis-
sues while delivering sufficient heating to the target volume.
HIFU’s main shortcomings, which were observed during
treatment, are related to this trade-off as well, namely, the
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1 Cranial left 24.3 Cold Solid 1.1 0.7 12.2 13.9 13.8 10.9 13.9 10.1
2 Caudal left 18.3 Hot Solid 0.8 0.2 13.1 5.4 9.3 5.1 13.8 12.6
3 Isthmal 13.6 Cold Echocomplex 4.3 2.2 16.2 11.0 23.2 19.9 24.2 21.4
4 Caudal right 14.7 Hot Echocomplex 1.7 0.6 11.4 6.6 16.0 16.2 20.0 12.6
5 Centro-cranial
right
14.4 Cold Solid 3.5 2.2 13.8 8.5 20.3 21.3 25.9 25.0
6 Cranial left 17.1 Cold Solid 1.0 0.3 9.0 6.6 16.3 8.3 15.4 11.3
7 Centro-caudal
right
21.4 Indifferent Echocomplex 3.8 3.3 15.3 18.1 18.2 14.5 29.2 25.4
8 Caudal left 23.7 Cold Echocomplex 7.7 3.0 21.2 8.8 25.4 27.6 29.8 25.6
9 Centro-caudal
left
23.6 Cold Echocomplex 4.0 3.5 18.5 17.2 27.8 28.4 16.1 15.0
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amount of volume that could actually be treated in rela-
tion to initial nodular volume was limited by four built-in
constrains of the EchoPulse®: (1) application to only one
layer of treatment sites, (2) maximum treatment depth of
approximately 2.8 cm, (3) security margins around sens-
ible structures and (4) only one direction of site alignment
of 90° to the skin.
Current experience with the device and TN treatment
in general argues against changing (1) since it would
lead to prolonging an already lengthy treatment whose
median duration was 62 min. At the same time, removing
this limitation might increase treatment coverage and,
with it, considerably increase therapy effectiveness. This
might be especially useful for larger TNs, since these are
more likely to have relevant masses above and/or below
the treatment layer.
Treatment depth limitation of HIFU has already been
reported in other indications [24]. This is due to the fact
that a sufficient heating of deeper layers of tissue requires
larger amounts of energy to be emitted, as more of it is
lost in pre-focal areas, which in turn can only handle lim-
ited heating per time unit without being damaged. The
EchoPulse® addresses this problem by increasing heat flux
from the non-targeted tissue the US pulse passes through
by cooling the overlying skin. Yet, median treatment time
is still 62 min and median ablated volume only 1.3 ml. More-
over, 3-month volume reduction of deeper lying nodules is
lower relative to that of shallower nodules, with correlation
of treatment depth and volume reduction being τ = −0.61
(p < 0.05). A potential solution for this could be utilization
of either a larger probe or multiple probes targeting the
same focal point from different angles, thus allocating en-
ergy lost in pre-focal tissue to more volume. Additionally,
more flexible probe positioning may make it possible to
send each pulse through a different part of overlaying tis-
sue and hence minimize inter-pulse treatment pauses.
Yonetsuji et al. [25] suggest that an increase in degrees
of probe rotation helps reduce skin burns, long treatment
time and incomplete ablation, which are the main prob-
lems of HIFU therapy in general. This indicates that (4)
indeed has been limiting treatment success.
Sufficient security margins (3) are an essential require-
ment considering our data showing effects of HIFU be-
yond the targeted area, as implied by nodular shrinkages
larger than the treated volumes. Specifically, this was ob-
served in three of our nine cases with reductions of 2.1,
1.4 and 4.7 ml induced when treating volumes of 1.3, 1.0
and 1.5 ml, respectively.
These off-focus lesions should be majorly situated
above the focal point, as there the pulse is more power-
ful than below it. Parafocal lesions should occur due to
heat conduction as well as convection by blood flow but
should only be marginal.The main reason for long treatment durations is that
after each pulse emission, the non-targeted area around
and especially above the nodule needs to cool down, which
takes time increasing with the energy absorbed in pre-focal
tissue. As noted, this could be addressed by larger, mul-
tiple, or more flexible probes.
Volume reduction
Turtulici et al. [12] found that a single RFA treatment of
larger benign non-functioning TNs (mean pre-ablation
volume 13.5 ml) could induce mean relative shrinkage of
72.6% after 6 months. Baek et al. [26] observed average
decreases of 82.6% for predominantly solid benign TNs
after the same period.
Ha et al. [27] who used HIFU for nodules with pre-
ablative volume of 9.7 ml were able to induce a mean
reduction of 87.2% after an average of 43.7 months. A
meta-analysis by Shin et al. [22] demonstrated that a
single RFA session induces reduction of 33% to 49% in
predominantly solid TNs after 1 month and 51% to 80%
after 6 months.
Korkusuz et al. [7] report volume reductions of 54.2%
3 months after MWA in benign cold TNs. Yue et al. [28]
induced shrinkages of 65% on average using MWA, mea-
sured 6 months after ablation.
Døssing et al. [10] report a median reduction of the
solid component volume of a cystic TN of 54% 6 months
after a combined therapy of cyst aspiration and subsequent
ILP. They also produced a median volume reduction of be-
nign cold solid TNs of 51% a median of 67 months after a
single ILP session [29]. They also compare ILP and RIT on
solitary autonomous nodules and found similar volume
reductions after 6 months on average of 44% and 47%,
respectively [30].
Compared to these values, the findings of this study
regarding a relative median shrinkage of 48.8% of relatively
small TNs after only 3 months are decent, especially
considering the technical constraints explained above
that were limiting treatment coverage.
Factors influencing success
As deeper lying TNs presented significantly smaller vol-
ume reductions (τ = −0.61, p < 0.05), pre-focal energy losses
appear to have been higher than anticipated. Continuous
intra-procedure power adjustment by “heat bubble” obser-
vation, as opposed to baseline only, might enable sufficient
focal heating by real-time treatment effect visualization.
The unexpected lack of relationship between planned
treatment volume and volume reduction may have been
due to patient movement causing site blurring (e.g.
swallowing can create tissue movement in a cranio-caudal
direction that does not necessarily induce laser-detectable
skin movement above 1 mm in a lateral or dorso-frontal
direction). Site blurring may cause energy pulses to be
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to being focused at a single point. This then results in lack
of sufficient heating of the targeted area, leading to sub-
optimal ablation.
The six cases in which nodular shrinkage was lower than
the treated volume do not necessarily need to be explained
by effectiveness-reducing effects like site blurring or lower
effectiveness in deeper lying TNs, as post-ablative nodular
shrinkage is not usually completed after 3 months.
The correlation of baseline nodular volume (τ = 0.38,
p > 0.05) with nodular shrinkage might be due to two dif-
ferent effects: off-focus lesions are more likely to lie within
the target TN if it is larger, and larger TNs obviously have
more potential for shrinkage measured in absolute volume
reduction. The reason for the correlation being neither
high nor significant could be explained by interfering ef-
fects such as site blurring, strong relevance of treatment
depth and small sample size.
The near non-correlation of total energy delivered per
nodule to nodular volume reduction (τ = 0.05, p > 0.05)
can be explained by this as well.
Cystic nodule shrinkage is generally better. Sung et al.
[31] report mean reduction values for such TNs at the
6-month follow-up of 96.9% and 93.3% after a single ses-
sion of EA or RFA, respectively.
In this study, however, partially cystic “echocomplex”
nodules did not yield significantly different volume reduc-
tions compared to solid ones (p > 0.05). In RFA and MWA,
cysts within, or even only infringing the effect radius,
should be sufficiently heated to ablate the adjacent cells.
With HIFU, however, only small doses of energy are emit-
ted per time. If, via heat conduction from neighbouring
tissue, this energy is distributed within a larger volume of
cyst liquid, threshold temperatures may never be reached.
Possibly, most cysts within “echocomplex” TNs were
too small for such effects to take place, as singular pulses
were able to deliver sufficient energy per micro-cyst. In
this study, all echocomplex TN presented a cystic compo-
nent of less than 25% of the total nodular volume.
Functional activity of thyroid tissue is independent of
its sensitivity to heating. As expected, hot nodules did
not yield significantly different volume reduction than
cold or indifferent ones (p > 0.05).
Treatment success prediction
Previous studies have shown that neither US elastography
[32,33] nor colour-coded duplex US [34] can replace
scintigraphy for assessing TNs, especially hot ones. The
relative uptake reduction values of this study were already
reported earlier [35] and ranged from 10% to 57%. This is
proof of normal thyroidal tissue lying in front and/or be-
hind the treated nodule remaining functionally intact.
The findings of this study suggest that the relative
target area background adjusted uptake reduction inrelation to total thyroidal uptake predicts nodular shrink-
age to a certain extent (τ = 0.66, p < 0.05). This is plausible
as uptake reductions are due to induced necrosis, which
in turn will be disintegrated over time and leads to nodu-
lar volume reduction. The reason for uptake reduction
correlating with absolute rather than relative volume
reduction (τ = 0.44, p > 0.05) may be due to two reasons.
Firstly, relative uptake reductions themselves are not
linearly dependent on successful treatment coverage, as
scintigraphic imaging is two-dimensional, and thus, up-
take in tissue lying in front or behind the nodule is never-
theless registered as lying in the target area. Secondly,
Kendall’s τ is a non-parametric rank correlation coeffi-
cient, and ranks between absolute and relative volume
reduction may change. In small samples, a single such
change might cost significance.
Conclusion
HIFU treatment of benign predominantly solid TNs is easy
to perform, non-invasive and appears to be safe. There is,
nevertheless, room for its improvement in terms of tech-
nical optimization to further increase treatment coverage
and decrease duration. With the current technology, the
method is already able to produce relative nodular volume
reduction rates similar to more established techniques
for local ablation. Considering HIFU’s advantages of non-
invasiveness, lower infection risk and no scar formation,
the method should be further explored. Especially for the
treatment of small shallow benign TNs, HIFU might prove
to be superior to alternative treatments. Specific issues
that should be addressed in the future include exploration
of the possible benefits of multiple procedures and long-
term outcome.
It is nevertheless important to note that this study’s
finding and conclusions are based on a small sample and
should be validated in larger trials.
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